

Consensus or Controversy? Documenting and Discussing Investigators' Approaches to the Use of Oral SERDs and Agents Targeting the PI3K/AKT/mTOR Pathway in Breast Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following descriptions best characterizes the study design of the INAVO123 trial for PIK3CA-mutant, hormone receptor (HR)-positive, HER2-negative breast cancer?
 - a. A Phase III study evaluating inavolisib/fulvestrant versus alpelisib/fulvestrant for relapsed/refractory advanced disease
 - b. A Phase III study evaluating the addition of inavolisib to a first-line CDK4/6 inhibitor with letrozole for endocrine-sensitive advanced disease**
 - c. A Phase III study evaluating the addition of inavolisib to an adjuvant CDK4/6 inhibitor with aromatase inhibitor therapy for localized disease
2. Which of the following outcomes best characterizes the clinical activity of giredestrant with everolimus based on ESR1 mutation status in the Phase III eVERA study for patients with HR-positive, HER2-negative metastatic breast cancer (mBC) previously treated with a CDK4/6 inhibitor?
 - a. A numerical but nonsignificant improvement in progression-free survival (PFS) for patients with ESR1-mutated disease
 - b. A significant improvement in PFS for patients with ESR1-mutated disease**
 - c. A significant improvement in PFS regardless of ESR1 mutation status
3. The Phase III CAMBRIA-2 study is evaluating camizestrant versus standard therapy for HR-positive, HER2-negative breast cancer in which of the following settings?
 - a. As initial adjuvant therapy for localized disease**
 - b. As extended-adjuvant therapy after standard endocrine therapy for localized disease
 - c. As first-line therapy for previously untreated metastatic disease
 - d. As second-line therapy for progressive metastatic disease
4. Available data suggest that gedatolisib-based regimens from the VIKTORIA-1 clinical trial platform are effective in ...
 - a. PIK3CA-mutant disease
 - b. PIK3CA wild-type disease
 - c. Both a and b**
 - d. Neither a nor b
5. Which of the following subgroups of patients benefited from the addition of capivasertib to fulvestrant in the CAPitello-291 study?
 - a. Patients who are CDK4/6 inhibitor-naïve
 - b. Patients who have previously received a CDK4/6 inhibitor
 - c. Both a and b**
 - d. Neither a nor b